Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released the updated National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the Commercial Health Insurance Innovative Drug Catalog for 2025, which includes 114 new drugs, 50 of which are Class 1 innovative drugs [1] - The total number of drugs in the National Medical Insurance Drug Catalog will increase to 3,253, with significant improvements in coverage for key areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1] - The introduction of the Commercial Health Insurance Innovative Drug Catalog is expected to alleviate payment challenges for high-value innovative drugs, providing an additional payment pathway beyond basic medical insurance [1] Group 2 - Zai Lab is in a rapid product expansion phase, with a rich pipeline of projects, and its clinical development of ZG006 is among the global leaders, potentially becoming the best in its class [2] - Zai Lab's self-developed drug, Jikangxi (sodium gikaxtin), has been included in the National Medical Insurance Drug Catalog following negotiations [2] - Junshi Biosciences has four commercialized products included in the 2025 National Medical Insurance Drug Catalog, with two new indications for Tuoyi (Tremelimumab) successfully added, and Junshida (Ongentys) being included for the first time [2]